IGFBP3 A-202C polymorphism and breast cancer susceptibility: a meta-analysis involving 33,557 cases and 45,254 controls
- PMID: 20084546
- DOI: 10.1007/s10549-010-0739-9
IGFBP3 A-202C polymorphism and breast cancer susceptibility: a meta-analysis involving 33,557 cases and 45,254 controls
Abstract
Published data on the association between insulin-like growth factor binding protein 3 (IGFBP3) A-202C polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between them. A total of 27 studies including 33,557 cases and 45,254 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated with IGFBP3 C allele when all studies were pooled into the meta-analysis (CC vs. AA: OR = 1.06, 95% CI = 1.02-1.11; dominant model: OR = 1.04, 95% CI = 1.00-1.07). In the subgroup analysis by ethnicity, significantly increased risk was found for Caucasians (AC vs. AA: OR = 1.04, 95% CI = 1.00-1.08; CC vs. AA: OR = 1.05, 95% CI = 1.01-1.10; dominant model: OR = 1.04, 95% CI = 1.00-1.08) and Asians (CC vs. AA: OR = 1.35, 95% CI = 1.02-1.78; recessive model: OR = 1.38, 95% CI = 1.05-1.82). When stratified by study design, statistically significantly elevated risk was found among population-based studies (CC vs. AA: OR = 1.06, 95% CI = 1.01-1.11; dominant model: OR = 1.03, 95% CI = 1.00-1.07). In the subgroup analysis by menopausal status, no statistically significantly increased risk was found among premenopausal or postmenopausal women. In conclusion, this meta-analysis suggests that the IGFBP3 C allele is a low-penetrant risk factor for developing breast cancer.
Similar articles
-
MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls.Breast Cancer Res Treat. 2010 Sep;123(2):549-55. doi: 10.1007/s10549-010-0783-5. Epub 2010 Feb 9. Breast Cancer Res Treat. 2010. PMID: 20143151
-
XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.Breast Cancer Res Treat. 2010 Nov;124(1):229-35. doi: 10.1007/s10549-010-0813-3. Epub 2010 Mar 5. Breast Cancer Res Treat. 2010. PMID: 20204500
-
Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects.Breast Cancer Res Treat. 2010 Jul;122(2):521-5. doi: 10.1007/s10549-009-0731-4. Epub 2010 Jan 7. Breast Cancer Res Treat. 2010. PMID: 20054636 Review.
-
TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects.Breast Cancer Res Treat. 2010 Sep;123(2):563-7. doi: 10.1007/s10549-010-0781-7. Epub 2010 Feb 9. Breast Cancer Res Treat. 2010. PMID: 20143152
-
XRCC3 5'-UTR and IVS5-14 polymorphisms and breast cancer susceptibility: a meta-analysis.Breast Cancer Res Treat. 2010 Jul;122(2):489-93. doi: 10.1007/s10549-009-0726-1. Epub 2010 Jan 5. Breast Cancer Res Treat. 2010. PMID: 20049524 Review.
Cited by
-
Ethnic background and genetic variation in the evaluation of cancer risk: a systematic review.PLoS One. 2014 Jun 5;9(6):e97522. doi: 10.1371/journal.pone.0097522. eCollection 2014. PLoS One. 2014. PMID: 24901479 Free PMC article.
-
Genetic architecture of mammographic density as a risk factor for breast cancer: a systematic review.Clin Transl Oncol. 2023 Jun;25(6):1729-1747. doi: 10.1007/s12094-022-03071-8. Epub 2023 Jan 13. Clin Transl Oncol. 2023. PMID: 36639603
-
Prognostic value of IGFBP2 in various cancers: a systematic review and meta-analysis.Cancer Med. 2022 Aug;11(16):3035-3047. doi: 10.1002/cam4.4680. Epub 2022 May 11. Cancer Med. 2022. PMID: 35546443 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous